Icon Plc ICLR

$162.05 +0.20 (0.12%)

Valuation

Market cap
12,392,370,000
Revenue TTM
$8,251,340,000
Net income TTM
$229,340,000
PE ratio
17.69
Forward PE
17.78
Profit margin
2.78%
Debt to equity
0.36

Trading

Volume
676,100
Avg volume
857,628
Day's range
$160.41 – $163.43
Shares out
76,567,000
Stochastic %K
10%
Beta
1.24
Analysts
Sell
Price target
$186.65

Price

Company profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinic...

Show more

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
353 1 291 2000
Website
https://www.iconplc.com
Address
South County Business Park, Leopardstown, Dublin, Ireland

Latest news

Stocktwits

Doozio Sep 15, 3:55 PM
$ICLR chop chop huckleberries n up da Roger YO go 🐒🍌🧠⏰♾️
0 replies
PrintingGains Sep 11, 1:10 AM
$ICLR 200$ stock
0 replies
Estimize Aug 26, 12:06 PM
Wall St is expecting 2.68 EPS for $ICLR Q3 [Reporting 10/28 AMC] http://www.estimize.com/intro/iclr?chart=historical&metric_name=eps&utm_co
0 replies
zero_vector Aug 10, 9:43 AM
$ICLR looks ready to bounce off the 50 day average (correction to my earlier post)
0 replies
zero_vector Aug 6, 10:50 AM
$ICLR nice uptrend dip bouncing off the 50 day average
0 replies
Estimize Jul 30, 8:03 PM
Wall St is expecting 2.71 EPS for $ICLR Q3 [Reporting 10/28 AMC] http://www.estimize.com/intro/iclr?chart=historical&metric_name=eps&utm_co
0 replies
StocktwitsEarnings Jul 29, 8:30 PM
$ICLR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.94 down -63.42% YoY • Reported revenue of $2.06B up 1.20% YoY • ICON plc is reaffirming its 2026 full-year financial guidance, with revenue expected in the range of $7,850 million to $8,150 million and adjusted diluted earnings per share between $10.00 and $11.00.
0 replies
OpenOutcrier Jul 28, 12:54 PM
$ICLR (+5.2% pre) ICON and Anthropic Plan AI to Spot Trial Enrollment Risks https://ooc.bz/l/108816
0 replies